Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of Alberta PSMA compound 17
- Development stage
- Unknown
- Lead developer
- University of Alberta
01
Overview
Univ. of Alberta PSMA compound 17: sourced facts only. name: "Compound 17 was identified as a novel high-affinity PSMA inhibitor (IC50 = 0.013 μM) suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer." [PMID:37465305]; target: "Compound 17 was identified as a novel high-affinity PSMA inhibitor (IC50 = 0.013 μM) suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer." [PMID:37465305]; developer: "Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2, Canada." [PMID:37465305]
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Univ. of Alberta PSMA compound 17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Univ. of Alberta PSMA compound 17.